On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -3.48% from the last session, before settling in for the closing price of $2.30. Price fluctuations for ZNTL have ranged from $2.13 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 45.10% at the time writing. With a float of $55.11 million, this company’s outstanding shares have now reached $71.15 million.
Let’s determine the extent of company efficiency that accounts for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 20.57%, while institutional ownership is 83.21%. The most recent insider transaction that took place on Jan 02 ’25, was worth 13,762. In this transaction Chief Scientific Officer of this company sold 4,411 shares at a rate of $3.12, taking the stock ownership to the 191,317 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Former Chief Medical Officer proposed sale 9,888 for $2.86, making the entire transaction worth $28,294.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.93% during the next five years compared to -50.05% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Looking closely at Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL), its last 5-days average volume was 2.8 million, which is a jump from its year-to-date volume of 2.12 million. As of the previous 9 days, the stock’s Stochastic %D was 13.55%. Additionally, its Average True Range was 0.27.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 2.72%, which indicates a significant decrease from 7.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.10% in the past 14 days, which was higher than the 91.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.13, while its 200-day Moving Average is $5.47. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $2.35. Second resistance stands at $2.48. The third major resistance level sits at $2.55. If the price goes on to break the first support level at $2.15, it is likely to go to the next support level at $2.08. Now, if the price goes above the second support level, the third support stands at $1.95.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,265K shares outstanding in the company with a market cap of 158.21 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -88,280 K.
